Lenzing AG
Lenzing Aktiengesellschaft, together with its subsidiaries, produces and markets regenerated cellulosic fibers for textiles and nonwovens. The company operates through Division Fiber, Division Pulp, and Others segments. It offers lyocell, modal, and viscose fibers for application in textiles and nonwovens products, such as denim, activewear, lingerie and nightwear, home and interiors, luxury text… Read more
Lenzing AG (0NCV) - Net Assets
Latest net assets as of September 2021: €1.92 Billion EUR
Based on the latest financial reports, Lenzing AG (0NCV) has net assets worth €1.92 Billion EUR as of September 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€5.10 Billion) and total liabilities (€3.18 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €1.92 Billion |
| % of Total Assets | 37.64% |
| Annual Growth Rate | 6.72% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 5.83 |
Lenzing AG - Net Assets Trend (2016–2020)
This chart illustrates how Lenzing AG's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Lenzing AG (2016–2020)
The table below shows the annual net assets of Lenzing AG from 2016 to 2020.
| Year | Net Assets | Change |
|---|---|---|
| 2020-12-31 | €1.73 Billion | +14.54% |
| 2019-12-31 | €1.51 Billion | +0.75% |
| 2018-12-31 | €1.50 Billion | +1.72% |
| 2017-12-31 | €1.48 Billion | +10.49% |
| 2016-12-31 | €1.34 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Lenzing AG's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 7.2% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2020)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €1.19 Billion | 68.83% |
| Common Stock | €27.57 Million | 1.59% |
| Other Components | €512.57 Million | 29.58% |
| Total Equity | €1.73 Billion | 100.00% |
Lenzing AG Competitors by Market Cap
The table below lists competitors of Lenzing AG ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Maravai Lifesciences Holdings Inc
NASDAQ:MRVI
|
$285.91 Million |
|
Banco Products (I) Limited
NSE:BANCOINDIA
|
$286.08 Million |
|
Pubmatic Inc
NASDAQ:PUBM
|
$286.11 Million |
|
Chengdu Huasun Group Inc Ltd
SHE:000790
|
$286.16 Million |
|
Flinders Resources Limited
V:FDR
|
$285.86 Million |
|
Altri SGPS SA
LS:ALTR
|
$285.84 Million |
|
ShaoYang Victor Hydraulics Co.Ltd
SHE:301079
|
$285.80 Million |
|
Nerdwallet Inc
NASDAQ:NRDS
|
$285.77 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Lenzing AG's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2019 to 2020, total equity changed from 1,513,006,000 to 1,732,947,000, a change of 219,941,000 (14.5%).
- Net income of 8,167,000 contributed positively to equity growth.
- Dividend payments of 28,750,000 reduced retained earnings.
- Share repurchases of 495,443,000 reduced equity.
- Other factors increased equity by 735,967,000.
Equity Change Factors (2019 to 2020)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €8.17 Million | +0.47% |
| Dividends Paid | €28.75 Million | -1.66% |
| Share Repurchases | €495.44 Million | -28.59% |
| Other Changes | €735.97 Million | +42.47% |
| Total Change | €- | 14.54% |
Book Value vs Market Value Analysis
This analysis compares Lenzing AG's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently Lenzing AG utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.50%
- • Asset Turnover: 0.39x
- • Equity Multiplier: 2.40x
- Recent ROE (0.47%) is below the historical average (10.84%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 16.84% | 10.54% | 0.81x | 1.96x | €91.41 Million |
| 2017 | 18.83% | 12.30% | 0.90x | 1.69x | €130.35 Million |
| 2018 | 9.92% | 6.85% | 0.83x | 1.75x | €-1.18 Million |
| 2019 | 8.12% | 5.83% | 0.67x | 2.06x | €-28.50 Million |
| 2020 | 0.47% | 0.50% | 0.39x | 2.40x | €-165.13 Million |
Industry Comparison
This section compares Lenzing AG's net assets metrics with peer companies in the same industry.
Industry Context
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Lenzing AG (0NCV) | €1.92 Billion | 16.84% | 1.66x | $285.86 Million |
| Nyfosa AB (0A0K) | $2.92 Billion | 39.50% | 2.88x | $973.31 Million |
| High Templar Tech Limited (0A2T) | $12.52 Billion | 4.70% | 0.13x | $255.82 Million |
| Strategy Inc (0A7O) | $51.04 Billion | -7.54% | 0.21x | $40.17 Billion |
| NACON SASU (0A9N) | $67.54 Million | 15.85% | 1.20x | $7.64 Million |
| Antin Infrastructure Partners (0AA5) | $23.79 Million | 108.98% | 1.09x | $573.10 Million |
| Truecaller AB Series B (0AA7) | $1.41 Billion | 18.30% | 0.20x | $281.60 Million |
| Brockhaus Technologies AG (0AAW) | $254.92 Million | -6.23% | 1.68x | $74.40 Million |
| Hyloris Pharmaceuticals S.A. (0AB6) | $48.06 Million | -24.09% | 0.32x | $71.96 Million |
| Kalray S.A. (0ABT) | $28.43 Million | -41.56% | 0.67x | $33.84 Million |
| Webuild S.p.A. (0BJP) | $1.43 Billion | 10.29% | 7.14x | $1.13 Billion |